Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An improved plasmid DNA expression vector for direct injection into skeletal muscle

J Hartikka1, M Sawdey, F Cornefert-Jensen

  • 1Department of Cell Biology, Vical Incorporated, San Diego, CA 92121, USA.

Human Gene Therapy
|June 20, 1996
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of the J/ψ Polarization with Respect to the Event Plane in Pb-Pb Collisions at the LHC.

Physical review letters·2023
Same author

Enhanced Deuteron Coalescence Probability in Jets.

Physical review letters·2023
Same author

First Measurement of Antideuteron Number Fluctuations at Energies Available at the Large Hadron Collider.

Physical review letters·2023
Same author

CAR T in patients with large B-cell lymphoma not fit for autologous transplant.

British journal of haematology·2023
Same author

Changing characteristics of post-COVID-19 syndrome: Cross-sectional findings from 458 consultations using the Stanford Hall remote rehabilitation assessment tool.

BMJ military health·2023
Same author

Hypertriton Production in p-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2022

Researchers enhanced a plasmid DNA vector (VR1205) for gene therapy. The modified VR1255 vector significantly increased gene expression, showing 46-fold higher luciferase levels for potential therapeutic applications.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Biotechnology

Background:

  • Plasmid DNA vectors are crucial for gene delivery.
  • Previous vector (VR1205) showed limited luciferase expression (6.5 ng/muscle).
  • Need for improved vectors with higher gene expression and reduced viral sequences.

Purpose of the Study:

  • To modify and optimize the VR1205 plasmid DNA vector.
  • To enhance gene expression levels for potential gene therapy applications.
  • To compare expression of modified vectors against the original VR1205.

Main Methods:

  • Systematic modification of VR1205 vector elements (promoter, enhancer, polyadenylation, etc.).
  • Intramuscular injection of 50 micrograms of vectors into murine quadriceps.

Related Experiment Videos

  • Quantification of luciferase expression at 7 days postinjection.

    • Main Results:

    • Modifications to promoter, enhancer, and intronic sequences had minimal or negative effects.
    • Optimizations in polyadenylation, termination, backbone, and gene sequence increased expression.
    • The VR1255 vector achieved 300 ng luciferase/muscle, a 46-fold increase over VR1205.

    Conclusions:

    • VR1255 is an optimized plasmid DNA vector with significantly enhanced gene expression.
    • The vector modifications offer a promising tool for gene therapy.
    • Further development could lead to more effective gene delivery systems.